Home Cart Sign in  
Chemical Structure| 156897-06-2 Chemical Structure| 156897-06-2

Structure of Licofelone
CAS No.: 156897-06-2

Chemical Structure| 156897-06-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Licofelone is a dual COX/LOX inhibitor being considered as a treatment for osteoarthritis.

Synonyms: ML-3000

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Licofelone

CAS No. :156897-06-2
Formula : C23H22ClNO2
M.W : 379.88
SMILES Code : O=C(O)CC1=C(C2=CC=C(Cl)C=C2)C(C3=CC=CC=C3)=C4N1CC(C)(C)C4
Synonyms :
ML-3000
MDL No. :MFCD00929900
InChI Key :UAWXGRJVZSAUSZ-UHFFFAOYSA-N
Pubchem ID :133021

Safety of Licofelone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
OVCAR8 20 µM 72 hours To evaluate the effect of Licofelone on reversing stem-like properties in ovarian cancer MCTS. Results showed Licofelone significantly reduced the expression of CD133, ALDH1A, KLF4, NANOG, and SOX2. Cancer Res. 2018 Aug 1;78(15):4370-4385
Bone marrow cells (IMCs) 2.5, 5, 10 μM 5 days To investigate the effect of Licofelone on the generation of IMCs. Results showed that Licofelone significantly suppressed the generation of Gr-1+ CD11b+ IMCs and Gr-1− F4/80+ macrophages. Front Immunol. 2016 Dec 5;7:537
B16F10luc2 melanoma cells 1, 5, 10, 20 μM 48 hours To evaluate the direct effect of Licofelone on melanoma cell growth and ROS production. Results showed that Licofelone had no significant effect on the viability and ROS production of B16F10luc2 melanoma cells. Front Immunol. 2016 Dec 5;7:537
Colon tumor spheroids 25 µM 14 days Evaluate the inhibitory effects of LFA-9 and licofelone on colon tumor spheroid formation. LFA-9 significantly inhibited colon tumor spheroid formation by 60.2%, while licofelone inhibited by 22.3%. J Inflamm Res. 2020 Dec 31;13:1261-1278
Mouse peritoneal macrophages 0.1–100 µM 24 hours Evaluate the inhibitory effects of LFA-9 and licofelone on PGE2 and LTB4 production in LPS-stimulated macrophages. LFA-9 inhibited PGE2 and LTB4 production, while licofelone inhibited PGE2, LTB4, and PGI2 production. J Inflamm Res. 2020 Dec 31;13:1261-1278
Rat peritoneal macrophages 0.1–100 µM 24 hours Evaluate the inhibitory effects of LFA-9 and licofelone on PGE2 and LTB4 production in LPS-stimulated macrophages. LFA-9 inhibited PGE2 and LTB4 production, while licofelone inhibited PGE2, LTB4, and PGI2 production. J Inflamm Res. 2020 Dec 31;13:1261-1278
THP1-human monocytes 0.1–100 µM 24 hours Evaluate the inhibitory effects of LFA-9 and licofelone on PGE2 and LTB4 production in LPS-stimulated macrophages. LFA-9 inhibited PGE2 and LTB4 production, while licofelone inhibited PGE2, LTB4, and PGI2 production. J Inflamm Res. 2020 Dec 31;13:1261-1278
Candida albicans (CA16) 16 mg/mL 24 hours Evaluate the synergistic antifungal effect of Licofelone combined with fluconazole against resistant C. albicans, showing a significant reduction in the MIC80 of fluconazole. Front Microbiol. 2017 Nov 7;8:2101
Candida albicans (CA10) 16 mg/mL 24 hours Evaluate the synergistic antifungal effect of Licofelone combined with fluconazole against resistant C. albicans, showing a significant reduction in the MIC80 of fluconazole. Front Microbiol. 2017 Nov 7;8:2101
RAW 264.7 cells 2.7 μM 24 hours To evaluate the effect of LCF-CSBN on M1 macrophage polarization, results showed that LCF-CSBN significantly reduced the expression of M1 marker iNOS and increased the expression of M2 marker CD206. Adv Sci (Weinh). 2025 Mar;12(9):e2411911
A1847 10 µM 72 hours To evaluate the anti-proliferative/cell killing activity of Licofelone in ovarian cancer multicellular tumor spheroids (MCTS). Results showed Licofelone exhibited higher activity in MCTS compared to 2D cultured cells. Cancer Res. 2018 Aug 1;78(15):4370-4385

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague Dawley rats MIA-induced OA model and ACLT + pMMx-induced OA model Intra-articular injection 40 μg Every 4 weeks for 8 weeks To evaluate the therapeutic effect of LCF-CSBN in vivo, results showed that LCF-CSBN significantly attenuated joint inflammation, oxidative stress, and cartilage degeneration. Adv Sci (Weinh). 2025 Mar;12(9):e2411911
NOD scid gamma (NSG) mice Ovarian cancer patient-derived xenograft (PDX) model Intraperitoneal injection 50 mg/kg To evaluate the effect of Licofelone in combination with paclitaxel on the survival of ovarian cancer PDX model mice. Results showed the median survival of the combination group (>141 days) was significantly longer than paclitaxel alone (115 days), licofelone alone (37 days), or vehicle (30 days). Cancer Res. 2018 Aug 1;78(15):4370-4385
C57BL/6 mice B16F10luc2 melanoma model Intravenous and subcutaneous injection 5 mg/kg Once every second day for 14 days To evaluate the effect of Licofelone combined with a vaccine on the survival rate and immune-suppressive cell populations in melanoma-bearing mice. Results showed that Licofelone combined with the vaccine significantly prolonged the survival time of mice and reduced the number of Gr-1+ CD11b+ IMCs and Gr-1? F4/80+ macrophages in the bone marrow and spleen. Front Immunol. 2016 Dec 5;7:537
Fischer (F344) rats Carrageenan-induced rat paw edema model Oral 400 ppm Single dose, measurements taken at 1-, 2-, 3-, 4-, 5- and 6-hours after carrageenan injection Evaluate the anti-inflammatory effects of LFA-9 and licofelone on carrageenan-induced rat paw edema. LFA-9 showed 70.4% edema inhibition at 3 hours post-injection, while licofelone showed 61.7%. J Inflamm Res. 2020 Dec 31;13:1261-1278
Galleria mellonella Larvae model infected with resistant C. albicans Injection 80 mg/mL Single dose, observed for 4 days Evaluate the in vivo antifungal activity of Licofelone combined with fluconazole, showing a significant increase in larval survival rate. Front Microbiol. 2017 Nov 7;8:2101
Male Sprague Dawley rats Paclitaxel-induced mechanical allodynia model Oral gavage 50 mg/kg Acute treatment, administered on day 7 or 9 after the first dose of paclitaxel Licofelone inhibits COX and LOX and/or directly interacts with CB receptors to produce antiallodynic effects in a rat model of PINP. Biomedicines. 2024 Jul 11;12(7):1545
Bovine Early osteoarthritis model In vitro culture 1 mg mL−1 24 hours Evaluate the uptake and retention time of Licofelone-PBAE conjugates in cartilage, showing an 18-fold increase in uptake and 37-fold prolongation in retention time. RSC Adv. 2024 Jan 2;14(1):15-28
A/J mice NNK-induced lung tumor model Dietary administration 200 or 400 ppm Continued for 17 or 34 weeks To evaluate the preventive effects of licofelone alone or in combination with DFMO on NNK-induced lung tumors. Results showed that licofelone significantly inhibited lung tumor formation, and the effect was more pronounced when combined with DFMO. Am J Cancer Res. 2016 May 1;6(5):894-909
Swiss H mice Mainstream cigarette smoke (MCS) exposure model Dietary administration 960 mg/kg diet 6 weeks starting after weaning To evaluate the early modulation by licofelone of pulmonary DNA and RNA alterations in smoke-free or MCS-exposed H mice after 10 weeks of exposure. Results showed that licofelone significantly attenuated MCS-induced DNA damage and oxidative DNA damage, and modulated the expression of various pulmonary microRNAs. Carcinogenesis. 2020 Mar 13;41(1):91-99

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.16mL

2.63mL

1.32mL

26.32mL

5.26mL

2.63mL

References

 

Historical Records

Categories